162 related articles for article (PubMed ID: 15947595)
1. Comparison of screen detected and clinically diagnosed prostate cancer in the European randomized study of screening for prostate cancer, section rotterdam.
van der Cruijsen-Koeter IW; Vis AN; Roobol MJ; Wildhagen MF; de Koning HJ; van der Kwast TH; Schröder FH
J Urol; 2005 Jul; 174(1):121-5. PubMed ID: 15947595
[TBL] [Abstract][Full Text] [Related]
2. Tumor characteristics and prognostic factors in two subsequent screening rounds with four-year interval within prostate cancer screening trial, ERSPC Rotterdam.
van der Cruijsen-Koeter IW; Roobol MJ; Wildhagen MF; van der Kwast TH; Kirkels WJ; Schröder FH
Urology; 2006 Sep; 68(3):615-20. PubMed ID: 17010732
[TBL] [Abstract][Full Text] [Related]
3. Disease-specific survival of men with prostate cancer detected during the screening interval: results of the European randomized study of screening for prostate cancer-Rotterdam after 11 years of follow-up.
Zhu X; van Leeuwen PJ; Bul M; Otto SJ; de Koning HJ; Bangma CH; Schröder FH; Roobol MJ
Eur Urol; 2011 Aug; 60(2):330-6. PubMed ID: 21601352
[TBL] [Abstract][Full Text] [Related]
4. Tumour features in the control and screening arm of a randomized trial of prostate cancer.
Postma R; van Leenders AG; Roobol MJ; Schröder FH; van der Kwast TH
Eur Urol; 2006 Jul; 50(1):70-5. PubMed ID: 16434136
[TBL] [Abstract][Full Text] [Related]
5. Prostate specific antigen testing and digital rectal examination before and during a randomized trial of screening for prostate cancer: European randomized study of screening for prostate cancer, Rotterdam.
Beemsterboer PM; de Koning HJ; Kranse R; Trienekens PH; van der Maas PJ; Schröder FH
J Urol; 2000 Oct; 164(4):1216-20. PubMed ID: 10992369
[TBL] [Abstract][Full Text] [Related]
6. Biochemical progression rates in the screen arm compared to the control arm of the Rotterdam Section of the European Randomized Study of Screening for Prostate Cancer (ERSPC).
Roemeling S; Roobol MJ; Gosselaar C; Schröder FH
Prostate; 2006 Jul; 66(10):1076-81. PubMed ID: 16637077
[TBL] [Abstract][Full Text] [Related]
7. Is it necessary to detect all prostate cancers in men with serum PSA levels <3.0 ng/ml? A comparison of biopsy results of PCPT and outcome-related information from ERSPC.
Schröder FH; Bangma CH; Roobol MJ
Eur Urol; 2008 May; 53(5):901-8. PubMed ID: 18262712
[TBL] [Abstract][Full Text] [Related]
8. Interval cancers in prostate cancer screening: comparing 2- and 4-year screening intervals in the European Randomized Study of Screening for Prostate Cancer, Gothenburg and Rotterdam.
Roobol MJ; Grenabo A; Schröder FH; Hugosson J
J Natl Cancer Inst; 2007 Sep; 99(17):1296-303. PubMed ID: 17728218
[TBL] [Abstract][Full Text] [Related]
9. Extent of prostate-specific antigen contamination in the Spanish section of the European Randomized Study of Screening for Prostate Cancer (ERSPC).
Luján M; Páez A; Pascual C; Angulo J; Miravalles E; Berenguer A
Eur Urol; 2006 Dec; 50(6):1234-40; discussion 1239-40. PubMed ID: 16704893
[TBL] [Abstract][Full Text] [Related]
10. Tumor characteristics in a population-based prostate cancer screening trial with prostate-specific antigen.
Mäkinen T; Tammela TL; Hakama M; Stenman UH; Rannikko S; Aro J; Juusela H; Määttänen L; Auvinen A
Clin Cancer Res; 2003 Jul; 9(7):2435-9. PubMed ID: 12855615
[TBL] [Abstract][Full Text] [Related]
11. Cancer detection and cancer characteristics in the European Randomized Study of Screening for Prostate Cancer (ERSPC)--Section Rotterdam. A comparison of two rounds of screening.
Postma R; Schröder FH; van Leenders GJ; Hoedemaeker RF; Vis AN; Roobol MJ; van der Kwast TH
Eur Urol; 2007 Jul; 52(1):89-97. PubMed ID: 17257742
[TBL] [Abstract][Full Text] [Related]
12. 4-year prostate specific antigen progression and diagnosis of prostate cancer in the European Randomized Study of Screening for Prostate Cancer, section Rotterdam.
Schröder FH; Raaijmakers R; Postma R; van der Kwast TH; Roobol MJ
J Urol; 2005 Aug; 174(2):489-94; discussion 493-4. PubMed ID: 16006878
[TBL] [Abstract][Full Text] [Related]
13. Metastatic disease of screen-detected prostate cancer : characteristics at diagnosis.
Roemeling S; Kranse R; Vis AN; Gosselaar C; van der Kwast TH; Schröder FH
Cancer; 2006 Dec; 107(12):2779-85. PubMed ID: 17109445
[TBL] [Abstract][Full Text] [Related]
14. Low all-cause mortality in the volunteer-based Rotterdam section of the European randomised study of screening for prostate cancer: self-selection bias?
Otto SJ; Schröder FH; de Koning HJ
J Med Screen; 2004; 11(2):89-92. PubMed ID: 15153324
[TBL] [Abstract][Full Text] [Related]
15. Results of a randomized, population-based study of biennial screening using serum prostate-specific antigen measurement to detect prostate carcinoma.
Hugosson J; Aus G; Lilja H; Lodding P; Pihl CG
Cancer; 2004 Apr; 100(7):1397-405. PubMed ID: 15042673
[TBL] [Abstract][Full Text] [Related]
16. Predictors of biological aggressiveness of prostate specific antigen screening detected prostate cancer.
Isola J; Auvinen A; Poutiainen M; Kakkola L; Järvinen TA; Määttänen L; Stenman UH; Tammela T; Hakama M; Visakorpi T
J Urol; 2001 May; 165(5):1569-74. PubMed ID: 11342919
[TBL] [Abstract][Full Text] [Related]
17. Detection of prostate cancer: the impact of the European Randomized Study of Screening for Prostate Cancer (ERSPC).
Schröder FH
Can J Urol; 2005 Feb; 12 Suppl 1():2-6; discussion 92-3. PubMed ID: 15780157
[TBL] [Abstract][Full Text] [Related]
18. Towards an optimal interval for prostate cancer screening.
van Leeuwen PJ; Roobol MJ; Kranse R; Zappa M; Carlsson S; Bul M; Zhu X; Bangma CH; Schröder FH; Hugosson J
Eur Urol; 2012 Jan; 61(1):171-6. PubMed ID: 21840117
[TBL] [Abstract][Full Text] [Related]
19. European randomized study of prostate cancer screening: first-year results of the Finnish trial.
Määttänen L; Auvinen A; Stenman UH; Rannikko S; Tammela T; Aro J; Juusela H; Hakama M
Br J Cancer; 1999 Mar; 79(7-8):1210-4. PubMed ID: 10098761
[TBL] [Abstract][Full Text] [Related]
20. The role of the digital rectal examination in subsequent screening visits in the European randomized study of screening for prostate cancer (ERSPC), Rotterdam.
Gosselaar C; Roobol MJ; Roemeling S; Schröder FH
Eur Urol; 2008 Sep; 54(3):581-8. PubMed ID: 18423977
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]